Nashiru Billa Selected Research

Curcumin

4/2023	Studies on anti-colon cancer potential of nanoformulations of curcumin and succinylated curcumin in mannosylated chitosan.
12/2022	A novel approach of encapsulating curcumin and succinylated derivative in mannosylated-chitosan nanoparticles.
4/2022	Curcumin and Derivatives in Nanoformulations with Therapeutic Potential on Colorectal Cancer.
1/2022	Prospects of Curcumin Nanoformulations in Cancer Management.
1/2022	Characterization and ex vivo evaluation of curcumin nanoethosomes for melanoma treatment.
1/2021	Is Curcumin at the Threshold of Therapeutic Effectiveness on Patients with Colon Cancer?-A Systematic Review.
12/2019	Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer.
12/2018	Pharmacokinetic and anti-colon cancer properties of curcumin-containing chitosan-pectinate composite nanoparticles.
5/2017	Mucoadhesive Chitosan-Pectinate Nanoparticles for the Delivery of Curcumin to the Colon.
4/2014	Cellular uptake and anticancer effects of mucoadhesive curcumin-containing chitosan nanoparticles.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nashiru Billa Research Topics

Disease

7	Colonic Neoplasms (Colon Cancer) 04/2023 - 05/2017
5	Neoplasms (Cancer) 01/2023 - 04/2014
5	Colorectal Neoplasms (Colorectal Cancer) 04/2022 - 04/2014
3	Melanoma (Melanoma, Malignant) 01/2022 - 02/2021
2	Mycoses (Diseases, Fungus) 08/2022 - 03/2019
1	Wounds and Injuries (Trauma) 11/2023
1	Surgical Wound Infection 11/2023
1	Infections 11/2023
1	Inflammation (Inflammations) 11/2023
1	Type 2 Diabetes Mellitus (MODY) 01/2022
1	Multiple Sclerosis 01/2022
1	Necrosis 01/2022
1	Phenylketonurias (Phenylketonuria) 01/2022
1	Pheochromocytoma 01/2022
1	Skin Neoplasms (Skin Cancer) 01/2022
1	Hepatoblastoma 01/2022
1	Drug-Related Side Effects and Adverse Reactions 01/2022
1	COVID-19 01/2022
1	Adenocarcinoma 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Carcinoma (Carcinomatosis) 01/2022

Drug/Important Bio-Agent (IBA)

10	CurcuminIBA 04/2023 - 04/2014
3	ChitosanIBA 04/2023 - 12/2018
2	Proteins (Proteins, Gene)FDA Link 11/2023 - 01/2022
2	Amphotericin B (Amphotericin)FDA LinkGeneric 08/2022 - 03/2019
1	LigandsIBA 02/2022
1	Immune Checkpoint InhibitorsIBA 02/2022
1	CTLA-4 AntigenIBA 02/2022
1	CytokinesIBA 02/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2022
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 02/2022
1	PhytochemicalsIBA 01/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2022
1	Guanosine Diphosphate (GDP)IBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	Interleukin-2 (IL2)IBA 01/2022
1	HDL LipoproteinsIBA 01/2022
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022
1	VLDL LipoproteinsIBA 01/2022
1	Malondialdehyde (Propanedial)IBA 01/2022
1	Methylcellulose (BFL)IBA 01/2022
1	Oxidoreductases (Dehydrogenase)IBA 01/2022
1	Peptide Hydrolases (Proteases)FDA Link 01/2022
1	Phosphates (Orthophosphate)IBA 01/2022
1	PhycocyaninIBA 01/2022
1	PhycoerythrinIBA 01/2022
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2022
1	PolymersIBA 01/2022
1	Transferrin Receptors (Transferrin Receptor)IBA 01/2022
1	SeleniumIBA 01/2022
1	Transferrin (beta 2 Transferrin)IBA 01/2022
1	Interleukin-4 (Interleukin 4)IBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	Thiobarbituric Acid Reactive SubstancesIBA 01/2022
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2022
1	Reactive Nitrogen SpeciesIBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022
1	allophycocyaninIBA 01/2022
1	phycocyanobilinIBA 01/2022
1	phycoerythrobilinIBA 01/2022
1	cellulose acetate phthalateIBA 01/2022
1	6-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA 01/2022
1	dimethyldioctadecylammonium (dimethyldioctadecylammonium chloride)IBA 01/2022
1	polyether sulfone (polyethersulfone)IBA 01/2022
1	phthalic acid (phthalate)IBA 01/2022
1	acrylic acid (acrylate)IBA 01/2022
1	mesoglycanIBA 01/2022
1	ethyl acrylateIBA 01/2022
1	didodecyldimethylammoniumIBA 01/2022
1	L 30 (L-30)IBA 01/2022
1	dioleoyl phosphatidylethanolamineIBA 01/2022
1	oxidized low density lipoproteinIBA 01/2022
1	AcidsIBA 01/2022
1	BromidesIBA 01/2022
1	BuffersIBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022
1	PhycobiliproteinsIBA 01/2022
1	Cell-Penetrating PeptidesIBA 01/2022
1	aspartic acid glycine arginineIBA 01/2022
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2022
1	TocotrienolsIBA 02/2021
1	citrus pectinIBA 12/2019
1	Cetuximab (Erbitux)FDA Link 12/2019

Therapy/Procedure

2	Therapeutics 01/2023 - 02/2022
1	Analgesia 11/2023
1	Sutures (Suture) 11/2023
1	Operative Surgical Procedures 11/2023
1	Immunotherapy 02/2022